Literature DB >> 28003431

Targeting the Hippo signalling pathway for cancer treatment.

Keisuke Nakatani1,2, Tomohiko Maehama3, Miki Nishio1,2, Hiroki Goto2, Wakako Kato2, Hirofumi Omori2, Yosuke Miyachi2, Hideru Togashi1, Yohei Shimono1, Akira Suzuki1,2.   

Abstract

The Hippo signalling pathway monitors cell-cell contact and external factors that shape tissue structure. In mice, tumourigenesis and developmental abnormalities are common consequences of dysregulated Hippo signalling. Expression of Hippo pathway components is also frequently altered in human tumours and correlates with poor prognosis and reduced patient survival. Thus, the Hippo pathway is an attractive anti-cancer target. Here, we provide an overview of the function and regulation of Hippo signalling components and summarize progress to date on the development of agents able to regulate Hippo signalling for cancer therapy.
© The Authors 2016. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  Cancer; Hippo; TAZ; Therapy; YAP1

Mesh:

Substances:

Year:  2017        PMID: 28003431     DOI: 10.1093/jb/mvw074

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  18 in total

1.  Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness.

Authors:  Hirofumi Omori; Kuniaki Sato; Takafumi Nakano; Takahiro Wakasaki; Satoshi Toh; Kenichi Taguchi; Takashi Nakagawa; Muneyuki Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-04       Impact factor: 4.553

2.  Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.

Authors:  Hirotoshi Soyama; Miki Nishio; Junji Otani; Toshiko Sakuma; Shintaro Takao; Shigeo Hara; Takaaki Masuda; Koshi Mimori; Shinya Toyokuni; John P Lydon; Kazuwa Nakao; Hiroshi Nishina; Takumi Fukumoto; Tomohiko Maehama; Akira Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-11       Impact factor: 12.779

3.  Engineering of Human Lactoferrin for Improved Anticancer Activity.

Authors:  Yu Pan; Niying Chua; Kaisheng Lim; Chun Loong Ho
Journal:  ACS Pharmacol Transl Sci       Date:  2021-07-19

4.  Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.

Authors:  Gabriele Picco; Elisabeth D Chen; Luz Garcia Alonso; Fiona M Behan; Emanuel Gonçalves; Graham Bignell; Angela Matchan; Beiyuan Fu; Ruby Banerjee; Elizabeth Anderson; Adam Butler; Cyril H Benes; Ultan McDermott; David Dow; Francesco Iorio; Euan Stronach; Fengtang Yang; Kosuke Yusa; Julio Saez-Rodriguez; Mathew J Garnett
Journal:  Nat Commun       Date:  2019-05-16       Impact factor: 14.919

5.  New Therapeutic Approach for Targeting Hippo Signalling Pathway.

Authors:  Leticia Dominguez-Berrocal; Erica Cirri; Xiguang Zhang; Laura Andrini; Gustavo H Marin; Sophie Lebel-Binay; Angelita Rebollo
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

Review 6.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

7.  Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.

Authors:  Paraskevi Xekouki; Emily J Lodge; Jakob Matschke; Alice Santambrogio; John R Apps; Ariane Sharif; Thomas S Jacques; Simon Aylwin; Vincent Prevot; Ran Li; Jörg Flitsch; Stefan R Bornstein; Marily Theodoropoulou; Cynthia L Andoniadou
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

Review 8.  Repurposing of Drugs Targeting YAP-TEAD Functions.

Authors:  Gian Marco Elisi; Matteo Santucci; Domenico D'Arca; Angela Lauriola; Gaetano Marverti; Lorena Losi; Laura Scalvini; Maria Laura Bolognesi; Marco Mor; Maria Paola Costi
Journal:  Cancers (Basel)       Date:  2018-09-14       Impact factor: 6.639

Review 9.  Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.

Authors:  Anello Marcello Poma; Liborio Torregrossa; Rossella Bruno; Fulvio Basolo; Gabriella Fontanini
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

Review 10.  New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?

Authors:  Michal Shreberk-Shaked; Moshe Oren
Journal:  Mol Oncol       Date:  2019-05-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.